Abstract: Photodynamic therapy (PDT) has become an effective treatment for certain types of solid tumors. The combination of PDT with other therapies has been extensively investigated in recent years to improve its effectiveness and expand its applications. This focused review summarizes the development of a prodrug system in which anticancer drugs are activated locally at tumor sites during PDT treatment. The development of a singlet-oxygen-sensitive linker that can be conveniently conjugated to various drugs and efficiently cleaved to release intact drugs is recapitulated. The initial design of prodrugs, preliminary efficacy evaluation, pharmacokinetics study, and optimization using quantitative systems pharmacology is discussed. Current treatment optimization in animal models using physiologically based pharmacokinetic (PBPK) modeling approach is also explored.

Keywords: photodynamic therapy; PDT; combination therapy; light-activatable prodrugs; singlet-oxygen-sensitive linker; aminoacrylate; paclitaxel; SN-38; Combretastatin A-4; quantitative systems pharmacology; pharmacokinetics; physiologically based pharmacokinetic modeling

1. Introduction

Photodynamic therapy (PDT) is a clinically approved treatment for a number of local cancers or local precancerous conditions, e.g., cancer of the esophagus, Barrett’s esophagus, endobronchial cancer, and actinic keratosis, and is currently under investigation to treat many others, including cancers of the skin, brain, mouth, stomach, prostate, cervix, and vagina [1,2]. A major mechanism by which PDT eradicates tumors is by locally generating a reactive oxygen species, i.e., singlet oxygen, which causes cellular damage leading to cell death. Singlet oxygen, however, has a short lifetime and can only diffuse a short distance (approximately 10–320 ns, 10–55 nm in cells) after it is generated, which leads to major, highly site-specific damage produced by PDT [3–11]. Given the highly local effect of PDT and the fact that incomplete ablation and recurrence are problems in PDT, partly resulting from residues of surviving cancer cells that escape PDT treatment, there has been a special interest in developing combination treatments involving PDT to make PDT more effective and expand its scope of applications [12–21]. In particular, the combination of PDT and systemically administered anticancer drugs has been extensively explored to achieve additive or synergistic antitumor effects [19,22–25]. More recent approaches have been designed to minimize systemic adverse effects of anticancer drugs based on various innovative ideas [12,20,26,27]. Reactive oxygen species were also used for triggering drug release from stimuli-responsive drug-releasing systems [28–32]. In our lab, we have been developing such prodrug systems in which the anticancer drug is released from the inert...
prodrug specifically at the tumor site when PDT treatment is initiated. The drug provides a sustained and extended cell-killing effect, in addition to local damage produced by PDT. While there are a number of other reviews about prodrugs and PDT [9,16,33–38], this case review summarizes the singlet-oxygen-activatable prodrug system developed in our lab, specifically focusing on development of our unique cleavable linker triggered by singlet oxygen, initial evaluation of photodynamic prodrugs utilizing the singlet-oxygen-sensitive linker, quantitative systems pharmacologic analysis, and current optimization aided by physiologically based pharmacokinetic modeling in animal models.

2. Development of Singlet-Oxygen-Sensitive Linker

Photocleavable bonds have long been investigated and used in numerous applications, such as in organic synthesis, drug delivery, and the study of intracellular biochemical processes (e.g., signaling pathways, gene expression) [39–45]. Light is a major component of PDT; however, the preferred wavelengths—to facilitate deeper penetration in tissue—are in the red and far-red regions, limiting the choices of linkers that are directly cleaved by such low-energy light [44–47]. In our prodrug system, we exploited a unique bond cleavage phenomenon mediated by singlet oxygen, which is generated during the PDT process, to overcome this problem. The cleavage mechanism is based on a well-known property of the double bond to participate in a [2+2] cycloaddition with singlet oxygen following decomposition to ultimately give carbonyl fragments via a dioxetane intermediate (Figure 1a) [48–56].

Figure 1. (a) [2+2] cycloaddition of singlet oxygen to a double bond to form dioxetane intermediate, followed by a bond breakage; (b, c) two other reactions competing with the [2+2] cycloaddition; sens = photosensitizer, R1–4 represent various substituents.

Such a cleavage mechanism has been thoroughly investigated and utilized by a number of investigators to, for example, prepare carbonyl-containing compounds in organic synthesis [54], create prodrugs from drugs bearing a carbonyl group [57], release drugs from liposomes [58–60], release and precipitate photosensitizers at targeted sites [61], or deliver photosensitizers from a glass tip [62]. While the [2+2] cycloaddition reactions of double bonds to singlet oxygen are either forbidden or unfavorably compete with Alder–Ene reaction and Diels–Alder [4+2] cycloaddition (Figure 1b,c), certain substitutions around the double bond were shown to facilitate the [2+2] reaction. Data from numerous reports showed that LUMO–HOMO interaction between singlet oxygen and alkene, the configuration around a double bond, and the availability of the hydrogen at the allyl position to the double bond play important roles in directing the reaction between singlet oxygen and an olefin. The reaction of singlet oxygen and an alkene can be exclusively directed through [2+2] cycloaddition, leading to clean products from decomposition of the dioxetane intermediate [50,51,55,63]. For example, various cis/trans-substituted alkenes were reported to react with singlet oxygen, followed by decomposition to give clean corresponding carbonyl compounds [49,57,64,65]. When the substituted double bonds were used as a photocleavable linker, a light-triggered release of greater than 90% of the conjugated reagents was reported, i.e., in [54,57,64,65]. Figure 2 represents an example of elegant design to create such activatable prodrugs invented and prepared from the Dolphin group [57].
Figure 2. A singlet-oxygen-activatable prodrug system for carbonyl-bearing drugs utilizing a singlet-oxygen-sensitive linker designed by the Dolphin group. Structures of photosensitizer and drugs investigated. Reproduced with permission from [57]. Note: In 5 and 6, R′ was ibuprofen moiety. Me = methyl group (CH₃−), Et = ethyl group (CH₃CH₂−), n-Pr = n-propyl group (CH₃CH₂CH₂−), and Ph = Phenyl group (C₆H₅−).

In an effort to search for a linker that offered facile conjugation conditions and released intact conjugated drugs, instead of drugs retaining a carbonyl group generated in linkers based on substituted double bonds (Figures 1a and 2), our lab turned attention to an acrylate linker bearing a heteroatom at β position. The investigation led to the discovery of an optimal β-aminoacrylate linker, which was shown to be stable for at least seven days in medium and without light when it was conjugated to a photosensitizer. Incorporation of the linker in drugs bearing an OH group was achieved under mild conditions (typically from 0 °C to room temperature in an aprotic solvent) and with high yield reactions (>80%) (Figure 3a). Cycloaddition with singlet oxygen and cleavage of the linker was fast and efficient. For example, more than 90% of a model prodrug of estrone was cleaved in 10 min (Table 1, entry 1) with a suitable photosensitizer and light source. Alternatively, using coumarin as a fluorescent probe, an almost quantitative release of the conjugated reagent was reported. Notably, intact original drugs/model agents bearing free OH groups were detected by gas chromatography/mass spectrometry after photolysis without the need of a hydrolase when using the β-aminoacrylate linker [66,67] (Figure 3b). The linker was used as a core component of all our subsequent prodrug designs and is referred to interchangeably as an aminoacrylate linker or singlet-oxygen-sensitive linker.

Figure 3. (a) Facile preparation of prodrug bearing a β-aminoacrylate linker from a hydroxyl-containing drug; (b) Activation of the prodrug and regeneration of original drug by singlet oxygen. DCC = dicyclohexyl carbodiimide, DMAP = 4-(dimethylamino) pyridine, R₁ and R₂ = alkyl groups.
Table 1. List of drugs, singlet-oxygen-activatable prodrugs, and fluorescent probes using aminoacrylate linker; cytotoxicity (IC$_{50}$) values.

| Entry | Drug       | Prodrug Structure (Name) | Wavelength; IC$_{50}$s (nM) without vs. with hv; Cell Line | Ref.     |
|-------|------------|--------------------------|-------------------------------------------------------------|---------|
| 1     | Estrone    | ![Estrone](image1)       | 690 nm                                                      | [66]    |
| 2     | SN-38      | ![SN-38](image2)        | 540 nm; 820 vs. 218; MCF-7                                  | [67]    |
| 3     | CA4        | ![CA4](image3)          | 540 nm; 116 vs. 13; MCF-7                                   | [67]    |
| 4     | Coumarin   | ![Coumarin](image4)     | 540 nm                                                      | [67]    |
| 5     | CA4        | ![CA4](image5)          | 690 nm; (a) 116 vs. 13; MCF-7                                | [68]    |
| 6     | CA4        | ![CA4](image6)          | 690 nm; (a) 173 vs. 6; MCF-7                                | [69,70] |

(a) 116 vs. 13; MCF-7
(b) 1802 vs. 1063; MCF-7
(b) 916 vs. 34; MCF-7
Table 1. Cont.

| Entry | Drug | Prodrug Structure (Name) | Wavelength; IC\textsubscript{50} (nM) without vs. with hv; Cell Line | Ref. |
|-------|------|--------------------------|-------------------------------------------------|------|
| 7     | CA4  | ![CA4 Structure](image)   | 690 nm; 116 vs. 13; MCF-7                          | [71] |
| 8     | PTX  | ![PTX Structure](image)   | 690 nm; 910 vs. 4; SKOV-3                         | [72] |
| 9     | CA4  | ![CA4 Structure](image)   | 531 nm; ~100% survival up to 1.25 µM with HAL (hexyl-5-aminolevulinate, 0.5 mM) vs. 5% survival at 0.1 µM with HAL (0.5 mM) | [73] |
| 10    | BODIPY | ![BODIPY Structure](image) | 531 nm | [73] |
3. Design of β-Aminoacrylate-Containing Prodrugs and Initial Biological Evaluation

One model drug (estrone), three anticancer drugs (SN-38, combretastatin A-4 (CA4), paclitaxel (PTX)), and a number of fluorescent probes were investigated in our lab as prodrugs and proimaging/probing agents activated by PDT using the β-aminoacrylate linker above (Table 1). The drugs contained either a phenolic or an alcoholic hydroxyl group, and they were conjugated to a β-aminoacrylate linker with an ester bond (structures in Table 1). Photosensitizers (PS) were either directly linked to prodrug/proagent molecules (Figure 4a, Table 1, entries 1–8, 11) or chemically separated from the drug moiety, but were localized to specific sites inside cells to which the prodrugs/proagents were also targeted (Figure 4b and Table 1, entries 9, 10, and 12).

![Prodrug Structure](image)

Table 1. Cont.

| Entry | Drug | Prodrug Structure (Name) | Wavelength; IC<sub>50</sub>s (nM) without vs. with hv; Cell Line | Ref. |
|-------|------|--------------------------|-------------------------------------------------|------|
| 11    | PTX  | ![Prodrug](image)         | 690 nm                                          | [11,74] |
| 12    | PTX  | ![Prodrug](image)         | 690 nm                                          | [11]  |

![Figure 4](image)

3. Design of β-Aminoacrylate-Containing Prodrugs and Initial Biological Evaluation

Initial testing showed a significant reduction in cytotoxicity (4.8- and 14.5-fold respectively, as measured by toxicity IC<sub>50</sub> against MCF-7 cells) of SN-38 and CA4 once the drugs were conjugated to a photosensitizer through the β-aminoacrylate linker (Table 1, entries 2 and 3). The toxicity was
recovered to a level comparable to that of the original drug upon activation of the prodrug (toxicity IC50 against MCF-7 cells was 218 nM and 13 nM, compared with 170 nM and 8 nM of SN-38 and CA4, respectively) (Table 1) [67].

Subsequently, CA4 and a fluorescent probe were conjugated to a near-IR photosensitizer through the aminoacrylate linker; and the activation of the drug/fluorescent agent was tested in tubulin polymerization assay, on cytotoxicity assay, and in mice (Table 1, entry 5a). CA4 conjugated to the photosensitizer was unable to inhibit tubulin polymerization (6% inhibition as compared to 100% inhibition of CA4). There was a noticeably significant difference in cytotoxicity between CA4 conjugated to the photosensitizer through the singlet-oxygen-sensitive linker and CA4 conjugated through a noncleavable linker (Table 1, entry 5a, b). The IC50 of cleavable conjugate in the dark was 164 nM, compared with 1802 nM of the noncleavable mimetic. Nevertheless, a significant difference in cytotoxicity was observed between the two in the presence of light. Photocleavable conjugate showed a six-fold decrease in IC50 cytotoxicity value (from 164 nM to 28 nM), compared with only 1.7-fold of the noncleavable analog (1802 nM to 1063 nM) (Table 1). More importantly, in a cell-based assay, the CA4 prodrug-PDT system showed the significant effect of killing nearby cells, compared with PDT alone (Figure 5). In mice, the combination system showed only minimal effect without illumination, but produced enhanced antitumor effects once activated with light, e.g., p < 0.05 between group G2 and group G4 in Figure 6. No significant signs of acute toxicity were observed during the treatment with the prodrug-PDT system in mice models [68].

The same drug (CA4) was conjugated to another photosensitizer that served as both singlet-oxygen-generator and fluorescent probe to determine an illumination time when the prodrug was at its optimal concentration at the target site. Silicon phthalocyanine (Sens/Fl, Table 1, entry 7) was chosen as a photosensitizer because it has a unique balance of both functionalities, i.e., quantum yield for singlet oxygen = 0.22 and fluorescence = 0.4 and a high molar extinction coefficient (ε = 150,000 M−1cm−1 at 675 nm) [69]. Two molecules of CA4 drug were linked to the sensitizer through either aminoacrylate linker (Table 1, entry 7a) or a noncleavable linker analog (Table 1, entry 7b) as a control. Regarding in vitro activity, both photocleavable and noncleavable compounds showed significantly lower inhibitory activity in a tubulin polymerization assay (23% and 17% for PDT-cleavable prodrug and noncleavable mimetic, respectively) compared with the parent drug CA4 (100%) at 3 μM concentration of each (p < 0.02 for both PDT-cleavable prodrug and noncleavable mimetic as compared to CA4 group). The toxicity IC50s against MCF-7 cells was determined to be 173 nM (PDT-cleavable prodrug) and 916 nM (noncleavable mimetic), compared with around 7 nM for CA4. Illumination restored the toxicity of the PDT-cleavable prodrug (IC50 = 6 nM). Significant cytotoxicity was also observed for the noncleavable prodrug with illumination, demonstrating the highly potent PDT effect of silicon phthalocyanine (IC50 = 34 nM). In mice, accumulation of fluorescence in tumors, reaching

![Figure 5. Extended cell-killing effect of the prodrug-PDT system, compared with PDT alone, demonstrated by fluorescence live cell imaging. (a) MCF-7 cells control, (b) MCF-7 cells treated with CMP–L–CA4 (50 nM), and (c) MCF-7 cells treated with a photosensitizer—core-modified porphyrin IY69 (5 μM). Irradiation with a 690 nm diode laser (11 mW/cm2 for 15 min) was performed only on the left side in each image. Reproduced with permission from [68].](image-url)
a maximum at around 24 h post injection, was observed when the animals received photocleavable prodrug or noncleavable analog (through polymer micelles formulation). Outstanding antitumor effects were observed in mice treated with PDT-cleavable prodrug, (1 \( \mu \)mol/kg + \( h \nu \) (100 mW/cm\(^2\))) or (2 \( \mu \)mol/kg + \( h \nu \) (200 mW/cm\(^2\))). Tumors shrank and remained nonmeasurable for almost 15 days in the PDT-cleavable prodrug and light treatment group, while tumor sizes reached > 800 mm\(^3\) after 12 days in the no-treatment control group. All mice treated with PDT-cleavable prodrug and light lived until day 30. Noncleavable mimic and light treatment (1 \( \mu \)mol/kg + \( h \nu \) (100 mW/cm\(^2\))) had a temporary impact on tumor size only until day 3, and the tumors grew back at a rate similar to that of the tumors in the no-treatment group (Figure 7). No mice experienced a significant loss in body weight during study duration (15 days), suggesting minimal acute toxicity of the combination treatment. The combination system was also shown to provide better antitumor effects in cell-based and animal models, as the release of CA4 could overcome the spatiotemporal limitations of \( ^1 \)O\(_2\) in PDT alone [70].
while a folate (FA) moiety was attached to the sensitizer on the other side. A polyethylene glycol (PEG) spacer of various lengths was placed between the FA and Sens/FI moiety (Table 1, entry 8). The folate receptor was targeted, as it was reported to be overexpressed in many tumors, such as ovarian, lung, colon, and breast cancers. Folate−drug conjugates have been developed and tested in cells, animal models, and human clinical trials with successful results. Additionally, PEG was introduced to help increase the solubility of the prodrugs, as they are highly hydrophobic and readily form aggregates in aqueous conditions. It was expected that PEG conjugation would reduce the aggregation and nonspecific uptake of the resulting conjugates by the cells or tumors, as well as increase the targeting capability of the construct. A cell-based assay showed that the FA-conjugated prodrugs were more potent than non-FA-conjugated analog. The PEG length affects solubility and cellular uptake of the prodrug, as well as its cytotoxicity upon activation. Upon activation with light, the cytotoxicity IC₅₀ against colon 26 cell lines was determined to be 17, 27, 40, 45, and 49 nM for a PEG of 45, 18, 1, 0, and 18 units in length without the FA group, respectively (Table 1, entry 8). Among the constructs listed above, in mice, a targeted prodrug containing a PEG of ~45 units was delivered to tumors most selectively. Selective and effective tumor damage was observed with minimal skin damage in a broad illuminated area, suggesting the contribution of the targeting FA group (Figure 8) [71].

![Figure 8. Selective tumor damage with minimal skin damage in a broad illuminated area of mice treated with a folate-receptor-targeted and nontargeted prodrug. Prodrug with a polyethylene glycol (PEG) length of ~45 in Table 1, entry 7 was used as an FA-targeted prodrug, and prodrug with PEG length of 18 units (nontargeted) in Table 1, entry 7 was used as a nontargeted prodrug. Prodrug dose was 2 µmol/kg, administered once. (i) Day 0 before illumination, (ii) day 1, (iii) day 6, and (iv) day 15 post illumination. Reproduced with permission from [71].](image-url)
In addition to directly linking CA4 to a photosensitizer, Bio et al. investigated the capability of activating aminoacrylate-linked CA4 in an intermolecular fashion by localizing both prodrug and photosensitizer to the mitochondria (Table 1, entries 9 and 10). This approach offers the flexibility of reducing prodrug size, which can help improve prodrug penetration and potentially selectivity in damaging the tumor due to multiplying selectivity of the two components in the system. Colocalization of the prodrug and photosensitizer to the mitochondria helps bring those components close enough to each other to ensure efficient cleavage of the linker mediated by singlet oxygen. The CA4 prodrug was targeted to the mitochondria by conjugating it to a rhodamine group (Table 1, entry 9). The photosensitizer, protoporphyrin IX, was formed in the mitochondria of cells from a hexyl-5-aminolevulinate precursor. Using a fluorescent mimetic, rapid and sufficient (72%) release of the conjugated moiety was estimated in the presence of light (Table 1, entry 10). In rat bladder cancer cells (AY-27), administration of the photosensitizer precursor and photoactivatable rhodamine-conjugated CA4 prodrug (0.1–1.25 µM) in the presence of light showed almost 100% cell killing, while no dark toxicity or phototoxicity of the photoactivatable conjugate in the absence of photosensitizer was observed, up to the prodrug concentration of 1.25 µM. When only the photosensitizer precursor was administered without prodrug, only about 50% of cell killing was observed. The increase in cytotoxicity was attributed to the combination effect of CA4 and PDT, compared with PDT alone [73].

Paclitaxel is another drug that was investigated with our PDT activating system [11,72,74]. PTX was connected to the aminoacrylate linker by an ester bond with an alcoholic hydroxyl group of PTX (Table 1, entry 7). Thapa et al. conjugated two PTX molecules to a silicon phthalocyanine moiety in a manner similar to that of a CA4 prodrug (Table 1, entries 6 and 8), using a facile synthesis, mild reaction conditions, and moderate yields. The PTX prodrug was shown to be stable in the dark in the presence of cells. An intact PTX molecule was rapidly released upon illumination of the prodrug (93% PTX was released under 30 min illumination at 690-nm laser light and 5.6 mW/cm²). Activity of PTX was abolished when it was conjugated to the sensitizer, as demonstrated by tubulin polymerization assay and cell-based toxicity assay (toxicity IC₅₀ against SKOV-3 cell lines was 910 nM, compared with 5 nM of PTX, a 190-fold reduction in toxicity). Once illuminated, the prodrug showed a strong cytotoxicity with an IC₅₀ of about 4 nM—comparable to that of PTX.

Thapa et al. further investigated the effect of PEG conjugation and folate receptor targeting on PTX prodrugs. Using a design similar to that of one of the CA4 prodrugs, PTX was connected to a silicon phthalocyanine on one side, and a folic acid (FA) moiety was attached to the sensitizer on the other side through a PEG of various lengths (~0, ~23, ~45, ~80, and ~114 PEG units) (Table 1, entries 7 and 11). Similar to what was observed with PEG-conjugated CA4 prodrugs, the PEG length affected nonspecific and folate-receptor-mediated uptake of the prodrugs. Prodrugs with medium-sized PEGs (~23, ~45, and ~80 PEG units) showed enhanced cellular uptake in folate-receptor-positive SKOV-3 cells, as compared with targeted prodrugs with the longest PEG (~114 PEG units) and with no PEG (12-fold increase in the intracellular prodrug accumulation at 24 h over that of no-PEG prodrug). In the dark, low toxicity was observed for all folate-PEG-conjugated PTX prodrugs, as demonstrated by >90% survival of SKOV-3 cells after 72 h of incubation with prodrugs at a concentration of 500 nM. In the presence of light, medium-sized FA-PEG-conjugated prodrugs showed more potent photocytotoxicity (IC₅₀ around 130 nM) than prodrugs with no PEG or longer PEG (~114 PEG units, IC₅₀ ~400 nM) [74].

PTX prodrug activated by PDT in an intermolecular system was also investigated. Bio et al. investigated conjugation of PTX to three different mitochondriotropic lipophilic cations, rhodamine, 4-carboxy-1-methylpyridinium chloride (CAT), and triphenylphosphonium (TPP), using photoactivatable aminoacrylate linker (Table 1, entry 12). The prodrugs were expected to accumulate in the mitochondria of cells and to be activated with light when the hexyl-5-aminolevulinate (HAL) precursor was administered. In a cell-based study, at a prodrug concentration of 1.25 µM with HAL, no significant cytotoxicity was observed in the absence of light. Upon illumination, however, 84%, 82%, and 80% of cells were killed with 0.25 µM rhodamine-, TPP-, and CAT-conjugated PTX prodrug, respectively.
Under the same conditions, PDT alone killed only about 40% of the cells, suggesting the enhanced cell killing effect of the PDT and singlet-oxygen-activatable prodrug combination system [11].

In the animal studies with our prodrugs, we did not observe any significant chronic toxicity monitored by visual observation and body weight change. That is because animals were treated only once in our standard treatment condition. However, more systemic study for chronic toxicity remains to be performed.

4. Challenges for Clinical Translation of Prodrug

Lack of efficacy is one of the top reasons for late-stage clinical failure of drug development [75]. This causes an incredible waste of time and money invested on early drug development. There is a missing link between early drug design and clinical outcome. Quantitative systems pharmacology (QSP) is an emerging field that investigates the relationship between drugs, biological systems, and the disease process using a computational and modeling technique on multiple scales from the molecule, organ, and rodent to patients [76]. QSP has been applied to many early drug developments to improve the probability of clinical success [77–79].

There are many kinetic processes involved in prodrug delivery. Several things need to be considered for our prodrug efficacy: 1. Once it goes into systemic circulation, it will go through elimination by the liver or kidney. With pegylated modification of the structure, it may be trapped in the reticuloendothelial system (RES), which prolongs its systemic circulation time [80]. However, pegylation can also prevent the prodrug from undergoing cell membrane binding and endocytosis; 2. Tumor vasculature and cancer cells are both potential targets of PDT damage. To target the cancer cell, our prodrug will be transported to the tumor via blood circulation. It will reach the individual cancer cell by extravasation into the tumor interstitium. Meanwhile, the concentration of the prodrug remaining in the tumor vasculature will decline due to systemic clearance. This will cause a loss of vasculature damage from PDT [81]; 3. The released anticancer agent will either bind to the intracellular target or diffuse to neighboring cells. As we can see here, all these processes produce opposite outcomes. It is critical to have a quantitative guideline to start an optimal experiment design. As such, QSP is an ideal tool to investigate the complexity of the system.

5. In Vitro Efficacy Evaluation of Prodrugs Guided by Quantitative Systems Pharmacology (QSP)

In our lab, we chose the Pc-(L-PTX)_2 (entry 8) prodrug to begin our in vitro investigation based on a QSP approach (Figure 9) [82]. We found that around 80% of our prodrug formed aggregates in medium, due to its high lipophilicity. Only 20% of free prodrug can be internalized into cells. However, disaggregation of Pc-(L-PTX)_2 was observed 9 h after incubation, which led to a higher intracellular accumulation of Pc-(L-PTX)_2 than observed with a control Pc-(NCL-PTX)_2 (a noncleavable mimetic of Pc-(L-PTX)_2) at 24 h. After 24 h incubation with prodrug, the cells were exposed to light illumination using a diode laser (690 nm) at 5.6 mW/cm^2 for 30 min. Three days after illumination, MTT assays were performed to evaluate PDT damage alone and PDT damage combined with PTX damage from prodrug. We found that our prodrug was more potent than PDT treatment alone (IC_{50} = 3.9 vs. 24 nM) due to released PTX [72]. This is what we called the bystander effect by the site-specific released anticancer drugs [83]. However, the in vitro results cannot always represent what happens in vivo. There were numerous discrepancies between the in vitro and in vivo antitumor effects [84]. To get a better insight into in vivo conditions, we replaced the medium immediately after illumination to mimic the in vivo condition of blood flow, a route for clearance of locally released drugs. The cytotoxicity of Pc-(L-PTX)_2 was largely diminished when we replaced the medium. In order to gain a systemic insight, we developed a quantitative mathematical model describing the intracellular trafficking of the prodrug and released drug. We used our developed model to evaluate the influence of each factor on the antitumor effects (in silico experiment) and to identify the key determinants of overall drug efficacy. We identified the following key highlights: 1. PDT effect is determined mainly by prodrug intracellular accumulation; 2. Bystander effect from released PTX is mostly influenced by its retention in the local
tumor area; 3. Target-binding affinity of the released anticancer drug is critical for anticancer efficacy. In this study, PTX was the linked anti-cancer agent. PTX is known to act by binding to β-tubulin in assembled microtubules and stabilizing them against disassembly. Based on our model simulation, its target binding affinity can significantly influence the prodrug efficacy in vivo. Among all taxane analogs, PTX showed a higher binding ability towards microtubules [85,86]. This result helped us to select the anticancer agent (PTX) for the following in vivo studies. The model can also be applied to other categories of anticancer agent selection.

**Figure 9.** Schematic diagram of the intracellular trafficking and dynamic model for light-responsive prodrug. After 24 h incubation of SKOV-3 cells with Pc-(L-PTX)$_2$, the cells were illuminated using a 690-nm diode laser (hv) at 5.6 mW/cm$^2$ for 30 min. The model components describing the kinetic and dynamic processes of the released paclitaxel (PTX) (blue arrows) only apply to the cleavable Pc-(L-PTX)$_2$. Reproduced with permission from [82].

### 6. PK Properties of the Prodrug

Several studies have reported the pharmacokinetic (PK) characteristics of PS itself [87]. There is a wide variation in PK profiles of different PSs. For example, Photofrin is reported to have a long-term half-life (156 days) in patients, while TOOKAD® undergoes a rapid elimination with a half-life of 1.3 h [88,89]. In most cases, PSs were found to accumulate in liver [90,91]. PS also accumulates in the spleen, lung, and kidney in several studies [92,93].

So far, only a few studies have investigated the PK of singlet-oxygen-activatable conjugates [94]. By adding the linker and anticancer drug, changes in structure, molecular weight, and physical characteristics may cause the alteration in PK profiles of photosensitizer conjugates. Furthermore, the anticancer drug is delivered through the PS vesicle. This can further change the PK of anticancer drugs in comparison to conventional administration.

The different PK profiles will impact the selection of light illumination time. PDT damages tumors via three well-known mechanisms: Direct cancer cell killing, vascular damage, and immune activation [95]. Prodrug accumulation between cancer cells and tumor vasculature varies based on its PK profiles. Different PK profiles will influence the time of light delivery selection: Drug-light interval (DLI), which is important for PDT mechanism and antitumor effect. The criteria for DLI selection are largely dependent on PK properties (PS accumulation in tumor, blood PS concentration, etc.). Therefore, it is important to understand prodrug PK before we start any treatment.

We chose FA–PEG$_{45}$–Pc-L-PTX to perform PK investigation because it showed the highest cancer cell accumulation in vitro [74]. The PK studies were performed in mice with an intravenous bolus
administration of 2 µmol/kg prodrug [96]. The plasma half-life of the prodrug was 8.6 h, which is longer than that of free PTX (T_{1/2} = 1.96 h). The longer remaining time in the vasculature gave us a flexible range to choose a DLI that could cause vascular damage. To add, we found a high accumulation of our prodrug in the tumor area due to the target delivery. The tumor concentration (>2 µM) was kept above IC_{50} from 12 to 48 h after prodrug administration [74]. Prodrug also accumulated in the liver, spleen, and kidney, which are the major organs for metabolism.

7. Treatment Optimization Aided by Physiologically Based Pharmacokinetic Modeling

With an in-depth understanding about significant events for prodrugs, released drugs, and key determinant variables in in vitro conditions, we further modified the prodrug for better in vivo efficacy (Figure 10). First, to achieve a higher and more selective accumulation in the tumor, we added a tumor-targeting group (folic acid, FA) and a spacer of PEG to our PTX prodrug [74]. According to our in vitro results, the modified PTX prodrug demonstrated an over 15-fold increase of uptake and 70% folate-receptor-mediated uptake [74]. While PTX is a highly lipophilic small molecule with a logP of 3.96 and molecular weight (MW) of 854 g/mole, the prodrug is much larger and more hydrophilic, with a logD of 7.4 and MW of ~4226 g/mol, due to the PEG moiety (for a PEG of 45 units in length) [74]. Due to its different physical characteristics, the in vivo PK study showed that PTX prodrug had a longer circulation half-life (T_{1/2} = 8.6 h vs. 1.96 h (PTX)) and restricted volume of distribution (Vss = 0.14 L/kg vs. 6.69 L/kg (PTX)) compared with free PTX [97].

PDT damages tumors via three well-known mechanisms: Direct cancer cell killing, vascular damage, and immune activation [95]. Direct cancer cell killing and vascular damage play an important role in immediate damage, while immune activation also contributes to sustained tumor damage [34]. Whether direct killing or vascular damage is more dominant depends on where the photosensitizer remains when illumination is made [98]. Distribution of photosensitizer in the tumor vasculature causes more vascular damage, while accumulation in cancer cells is better for direct killing. Based on our prodrug PK, we found that most of the prodrug remained in the plasma at an early time point (<1 h) and accumulated in the tumor after 9 h. We selected three different drug light intervals (DLIs = 0.5 h, 9 h, and 48 h) to test its antitumor efficacy [96].

In this study, PTX was delivered through our prodrug. To predict the amount of PTX released in the tumor with different DLIs, we built a physiologically based pharmacokinetic (PBPK) model to describe (1) tissue distribution of the PTX prodrug, (2) intracellular delivery of the PTX prodrug, and (3) biodistribution of released PTX [96]. As we mentioned above, PTX was delivered and released in the tumor through the prodrug system. Therefore, the released PTX PK profile was different to that of free PTX. We applied our PBPK model to predict released PTX kinetics in the tumor and plasma (Figure 11). Because blood flow to the tumor (Q_T) was influenced by antivascular effects from PDT, we simulated various released PTX kinetics profiles with different Q_T values. Interestingly, we found that the retention of released PTX was significantly impacted by Q_T values. PTX was quickly cleared from the tumor under a normal blood flow rate. However, PTX could remain in the tumor for over 24 h if the tumor capillary was completely blocked. Based on the simulation results, we hypothesized that the combination effect of PDT and PTX could be enhanced by optimized DLIs. We selected three different DLIs (0.5, 9, and 48 h) based on the prodrug PK profile to test its anticancer efficacy. The in vivo results demonstrated that the 9 h DLI had the best anticancer efficacy. At 9 h DLI, there was a balanced distribution of prodrug in the plasma and tumor, which could lead to both direct cancer cell killing and vascular damage. The damaged vasculature in the tumor area slowed the blood/tumor flow rate, which helped the PTX to remain in the tumor area [96].

With the in-depth understanding of prodrug PK and the help of advanced mathematical models, we can better design our future study. There will be a greater possibility to translate our preclinical results to clinical applications.
Aminoarylate linker was readily cleaved by illumination on the photosensitizer both in vitro and in vivo. QSP has become an essential tool for us to understand the pharmacokinetics and pharmacodynamics of the prodrug and clinical translation.

8. Conclusions

In recent years, significant progress has been made in developing advanced combination therapies involving PDT and chemotherapy without major systemic side effects. Our unique PDT (i.e., singlet-oxygen)-activatable prodrug system has demonstrated promise. Aminoarylate linker was readily cleaved by illumination on the photosensitizer both in vitro and in vivo. QSP has become an essential tool for us to understand the pharmacokinetics and pharmacodynamics of the prodrug and to optimize the efficacy of the prodrug in preclinical models. We were able to demonstrate effective and long-term control of local tumors using small and large tumor models under the optimized conditions. Currently, we are advancing our singlet-oxygen-activatable prodrug strategy in various angles, such as broader adaptability of functional groups for the singlet-oxygen-cleavable linker, bimolecular activation, QSP modeling incorporating more pharmacodynamics, tuning mechanism and pharmacology of prodrugs, and clinical translation.
Author Contributions: L.N. and M.L. wrote the manuscript and participated in some of the cited works. Y.Y. and S.W. conceived and led the project, and drafted and revised the manuscript.

Funding: This research was funded by the National Institute of General Medical Sciences of the National Institutes of Health (R01GM113940), DoD (Breast Cancer Research Program (W81XWH-14-1-0392)), and (Peer-Reviewed Cancer Research Program (W81XWH-17-1-0226)). The views and opinions of and endorsements by the authors do not reflect those of the U.S. Army or the DoD.

Acknowledgments: The authors would like to thank Kathy Kyler for editorial assistance in revising the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Dougherty, T.J.; Gomer, C.J.; Henderson, B.W.; Jori, G.; Kessel, D.; Korbelik, M.; Moan, J.; Peng, Q. Photodynamic therapy. *J. Natl. Cancer Inst.* 1998, 90, 889–905. [CrossRef] [PubMed]
2. van Straten, D.; Mashayekhi, V.; de Bruijn, H.S.; Oliveira, S.; Robinson, D.J. Oncologic photodynamic therapy: Basic principles, current clinical status and future directions. *Cancers (Basel)* 2017, 9, 19. [CrossRef] [PubMed]
3. Skovsen, E.; Snyder, J.W.; Lambert, J.D.C.; Ogilby, P.R. Lifetime and diffusion of singlet oxygen in a cell. *J. Phys. Chem. B* 2005, 109, 8570–8573. [CrossRef] [PubMed]
4. Moan, J. On the diffusion length of singlet oxygen in cells and tissues. *J. Photochem. Photobiol. B: Biol.* 1990, 6, 343–344. [CrossRef]
5. Firey, P.A.; Jones, T.W.; Jori, G.; Rodgers, M.A.J. Photoexcitation of zinc phthalocyanine in mouse myeloma cells: The observation of triplet states but not of singlet oxygen. *Photochem. Photobiol.* 1988, 48, 357–360. [CrossRef] [PubMed]
6. Wilkinson, F.; Helman, W.P.; Ross, A.B. Rate constants for the decay and reactions of the lowest electronically excited singlet state of molecular oxygen in solution. An expanded and revised compilation. *J. Phys. Chem.* Ref. Data 1995, 24, 663–677. [CrossRef]
7. Egorov, S.Y.; Kamalov, V.F.; Koroteev, N.I.; Krasnovsky, A.A.; Toleutaev, B.N.; Zinukov, S.V. Rise and decay kinetics of photosensitized singlet oxygen luminescence in water. Measurements with nanosecond time-correlated single photon counting technique. *Chem. Phys. Lett.* 1989, 163, 421–424. [CrossRef]
8. Dysart, J.S.; Patterson, M.S. Characterization of photofrin photobleaching for singlet oxygen dose estimation during photodynamic therapy of murine cells in vitro. *Phys. Med. Biol.* 2005, 50, 2597–2616. [CrossRef]
9. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Giorgetti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic therapy of cancer: An update. *CA Cancer J. Clin.* 2011, 61, 250–281. [CrossRef]
10. Schweitzer, C.; Schmidt, R. Physical mechanisms of generation and deactivation of singlet oxygen. *Chem. Rev. 2003, 103, 1685–1757. [CrossRef]
11. Bio, M.; Mahabubur, K.M.; Lim, I.; Rajaputra, P.; Hurst, R.E.; You, Y. Singlet oxygen-activatable paclitaxel prodrugs via intermolecular activation for combined pdt and chemotherapy. *Bioorg. Med. Chem. Lett.* 2019, 29, 1537–1540. [CrossRef] [PubMed]
12. Spring, B.Q.; Rizvi, I.; Xu, N.; Hasan, T. The role of photodynamic therapy in overcoming cancer drug resistance. *Photochem. Photobiol. Sci.* 2015, 14, 1476–1491. [CrossRef] [PubMed]
13. Rizvi, I.; Celli, J.P.; Evans, C.L.; Abu-Yousif, A.O.; Muzikansky, A.; Pogue, B.W.; Finkelstein, D.; Hasan, T. Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. *Cancer Res.* 2010, 70, 9319–9328. [CrossRef] [PubMed]
14. Rizvi, I.; Dinh, T.A.; Yu, W.; Chang, Y.; Sherwood, M.E.; Hasan, T. Photoinmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: Perspective and results. *Isr. J. Chem.* 2012, 52, 776–787. [CrossRef] [PubMed]
15. Spring, B.Q.; Abu-Yousif, A.O.; Palanisami, A.; Rizvi, I.; Zheng, X.; Mai, Z.; Anbil, S.; Sears, R.B.; Mensah, L.B.; Goldschmidt, R.; et al. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. *Proc. Natl. Acad. Sci. USA* 2014, 111, E933–E942. [CrossRef]
16. Dolmans, D.E.J.G.J.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. *Nat. Rev. Cancer* 2003, 3, 380–387. [CrossRef]
17. Li, L.-B.; Xie, J.-M.; Zhang, X.-N.; Chen, J.-Z.; Luo, Y.-L.; Zhang, L.-Y.; Luo, R.-C. Retrospective study of photodynamic therapy vs photodynamic therapy combined with chemotherapy and chemotherapy alone on advanced esophageal cancer. *Photodiagn. Photodyn. Ther.* 2010, 7, 139–143. [CrossRef]

18. Verma, S.; Watt, G.M.; Mai, Z.; Hasan, T. Strategies for enhanced photodynamic therapy effects. *Photochem. Photobiol.* 2007, 83, 996–1005. [CrossRef]

19. Postiglione, I.; Chiaviello, A.; Palumbo, G. Enhancing photodynamic therapy efficacy by combination therapy: Dated, current and oncoming strategies. *Cancers (Basel)* 2011, 3, 2597–2629. [CrossRef]

20. Luo, D.; Carter, K.A.; Miranda, D.; Lovell, J.F. Chemophototherapy: An emerging treatment option for solid tumors. *Adv. Sci.* 2016, 4, 1600106. [CrossRef]

21. Yi, X.; Dai, J.; Han, Y.; Xu, M.; Zhang, X.; Zhen, S.; Zhao, Z.; Lou, X.; Xia, F. A high therapeutic efficacy by combination of polymeric prodrug nano-assembly for a combination of photodynamic therapy and chemotherapy. *Commun. Biol.* 2018, 1, 202. [CrossRef] [PubMed]

22. Broekgaarden, M.; Rizvi, I.; Bulin, A.L.; Petrovic, L.; Goldschmidt, R.; Massodi, I.; Celli, J.P.; Hasan, T. Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. *Oncotarget* 2018, 9, 13009–13022. [CrossRef] [PubMed]

23. Mallidi, S.; Anbil, S.; Bulin, A.L.; Obaid, G.; Ichikawa, M.; Hasan, T. Beyond the barriers of light penetration: Strategies, perspectives and possibilities for photodynamic therapy. *Theranostics* 2016, 6, 2458–2487. [CrossRef] [PubMed]

24. Nahabedian, M.Y.; Cohen, R.A.; Contino, M.F.; Terem, T.M.; Wright, W.H.; Berns, M.W.; Wile, A.G. Combination cytotoxic chemotheraphy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. *J. Natl. Cancer Inst.* 1988, 80, 739–743. [CrossRef]

25. Zuluaga, M.F.; Lange, N. Combination of photodynamic therapy with anti-cancer agents. *Curr. Med. Chem.* 2008, 15, 1655–1673. [CrossRef]

26. Peterson, C.M.; Shah, J.G.; Sun, Y.; Kopeckova, P.; Minko, T.; Straight, R.C.; Kopecek, J. Hpma copolymer delivery of chemotherapy and photodynamic therapy in ovarian cancer. *Adv. Exp. Med. Biol.* 2003, 519, 101–123.

27. Reessing, F.; Szymanski, W. Beyond photodynamic therapy: Light-activated cancer chemotherapy. *Curr. Med. Chem.* 2017, 24, 4905–4950.

28. Deng, Z.; Hu, J.; Liu, S. Reactive oxygen, nitrogen, and sulfur species (ronss)-responsive polymersomes for triggered drug release. *Macromol. Rapid Commun.* 2017, 38, 1600685. [CrossRef]

29. Xu, Q.; He, C.; Xiao, C.; Chen, X. Reactive oxygen species (ros) responsive polymers for biomedical applications. *Macromol. Biosci.* 2016, 16, 635–646. [CrossRef]

30. Callaghan, S.; Senge, M.O. The good, the bad, and the ugly - controlling singlet oxygen through design of photosensitizers and delivery systems for photodynamic therapy. *Photochem. Photobiol. Sci.* 2018, 17, 1490–1514. [CrossRef]

31. Dariva, C.G.; Coelho, J.F.J.; Serra, A.C. Near infrared light-triggered nanoparticles using singlet oxygen photocleavage for drug delivery systems. *J. Control. Release* 2019, 294, 337–354. [CrossRef] [PubMed]

32. Cadahia, J.P.; Previtali, V.; Troelsen, N.S.; Clausen, M.H. Prodrug strategies for targeted therapy triggered by reactive oxygen species. *MedChemComm* 2019, 10, 1531–1549. [CrossRef] [PubMed]

33. Huang, Z. A review of progress in clinical photodynamic therapy. *Technol. Cancer Res. Treat.* 2005, 4, 283–293. [CrossRef] [PubMed]

34. Castano, A.P.; Mroz, P.; Hamblin, M.R. Photodynamic therapy and anti-tumour immunity. *Nat. Rev. Cancer* 2006, 6, 535–545. [CrossRef]

35. Srinivasasaroa, M.; Low, P.S. Ligand-targeted drug delivery. *Chem. Rev.* 2017, 117, 12133–12164. [CrossRef]

36. Rautio, J.; Meanwell, N.A.; Di, L.; Hageman, M.J. The expanding role of prodrugs in contemporary drug design and development. *Nat. Rev. Drug Discov.* 2018, 17, 559. [CrossRef]

37. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Järvinen, T.; Savolainen, J. Prodrugs: Design and clinical applications. *Nat. Rev. Drug Discov.* 2008, 7, 255. [CrossRef]

38. Triesscheijn, M.; Baas, P.; Schellens, J.H.M.; Stewart, F.A. Photodynamic therapy in oncology. *Oncologist* 2006, 11, 1034–1044. [CrossRef]

39. Leriche, G.; Chisholm, L.; Wagner, A. Cleavable linkers in chemical biology. *Bioorgan. Med. Chem.* 2012, 20, 571–582. [CrossRef]
40. Mayer, G.; Heckel, A. Biologically active molecules with a “light switch”. *Angew. Chem. Int. Ed.* 2006, 45, 4900–4921. [CrossRef]
41. Klán, P.; Solomek, T.; Bochot, C.G.; Blanc, A.; Givens, R.; Rubina, M.; Popik, V.; Kostikov, A.; Wirz, J. Photoremovable protecting groups in chemistry and biology: Reaction mechanisms and efficacy. *Chem. Rev.* 2013, 113, 119–191. [CrossRef]
42. Lee, H.-M.; Larson, D.R.; Lawrence, D.S. Illuminating the chemistry of life: Design, synthesis, and applications of “caged” and related photoresponsive compounds. *ACS Chem. Biol.* 2009, 4, 409–427. [CrossRef]
43. Brieye, C.; Rohrbach, F.; Gottschalk, A.; Mayer, G.; Heckel, A. Light-controlled tools. *Angew. Chem. Int. Ed.* 2012, 51, 8446–8476. [CrossRef]
44. Hansen, M.J.; Velena, W.A.; Lerch, M.M.; Szymanski, W.; Feringa, B.L. Wavelength-selective cleavage of photoprotecting groups: Strategies and applications in dynamic systems. *Chem. Soc. Rev.* 2015, 44, 3358–3377. [CrossRef]
45. Bardhan, A.; Deiters, A. Development of photolabile protecting groups and their application to the optochemical control of cell signaling. *Curr. Opin. Struct. Biol.* 2019, 57, 164–175. [CrossRef]
46. Gorka, A.P.; Nani, R.R.; Zhu, J.; Mackem, S.; Schmermann, M.J. A near-ir uncaging strategy based on cyanine photochemistry. *J. Am. Chem. Soc.* 2014, 136, 14153–14159. [CrossRef]
47. Shell, T.A.; Shell, J.R.; Rodgers, Z.L.; Lawrence, D.S. Tunable visible and near-ir photoactivation of light-responsive compounds by using fluorophores as light-capturing antennas. *Angew. Chem. Int. Ed.* 2014, 53, 875–878. [CrossRef]
48. Schaap, A.P.; Faler, G.R. Mechanism of 1, 2-cycloaddition of singlet oxygen to alkenes. Trapping a perepoxide intermediate. *J. Am. Chem. Soc.* 1973, 95, 3381–3382. [CrossRef]
49. Mazur, S.; Foote, C.S. Chemistry of singlet oxygen. IX. Stable dioxetane from photooxygenation of tetramethoxyethylene. *J. Am. Chem. Soc.* 1970, 92, 3225–3226. [CrossRef]
50. Foote, C.S.; Lin, J.W.P. Chemistry of singlet oxygen. VI. Photooxygenation of enamines: Evidence for an intermediate. *Tetrahedron Lett.* 1968, 9, 3267–3270. [CrossRef]
51. Kearns, D.R. Selection rules for singlet-oxygen reactions. Concerted addition reactions. *J. Am. Chem. Soc.* 1969, 91, 6554–6563. [CrossRef]
52. Fenical, W.H.; Kearns, D.R.; Radlick, P. Mechanism of the addition of 1.Delta.G excited oxygen to olefins. Evidence for a 1,2-dioxetane intermediate. *J. Am. Chem. Soc.* 1969, 91, 3936–3938. [CrossRef]
53. Frankel, E.N. Chemistry of free radical and singlet oxidation of lipids. *Prog. Lipid Res.* 1984, 23, 197–221. [CrossRef]
54. Huber, J.E. Photooxygenation of enamines—A partial synthesis of progesterone. *Tetrahedron Lett.* 1968, 9, 3271–3272. [CrossRef]
55. Foote Christopher, S. Mechanism of addition of singlet oxygen to olefins and other substrates. *Pure Appl. Chem.* 1971, 27, 635–646. [CrossRef]
56. Bartlett, P.D.; Schaap, A.P. Stereospecific formation of 1, 2-dioxetanes from cis- and trans-diethoxyethylenes by singlet oxygen. *J. Am. Chem. Soc.* 1970, 92, 3223–3225. [CrossRef]
57. Jiang, M.Y.; Dolphin, D. Site-specific prodrug release using visible light. *J. Am. Chem. Soc.* 2008, 130, 4236–4237. [CrossRef]
58. Eisenberg, W.C.; Taylor, K.; Grossweiner, L.I. Lysis of egg phosphatidylcholine liposomes by singlet oxygen generated in the gas phase. *Photochem. Photobiol.* 1984, 40, 55–58. [CrossRef]
59. Thompson, D.H.; Gerasimov, O.V.; Wheeler, J.J.; Rui, Y.; Anderson, V.C. Triggerable plasmalogens: Improvement of system efficiency. *Biochim. Biophys. Acta* 1996, 1279, 25–34. [CrossRef]
60. Anderson, V.C.; Thompson, D.H. Triggered release of hydrophilic agents from plasmalogen liposomes using visible light or acid. *Biochim. Biophys. Acta* 1992, 1109, 33–42. [CrossRef]
61. Ruebner, A.; Yang, Z.; Leung, D.; Breslow, R. A cycloextrin dimer with a photocleavable linker as a possible carrier for the photosensitizer in photodynamic tumor therapy. *Proc. Natl. Acad. Sci. USA* 1999, 96, 14692–14693. [CrossRef] [PubMed]
62. Zamadar, M.; Ghosh, G.; Mahendran, A.; Minnis, M.; Kruft, B.I.; Ghogare, A.; Aebisher, D.; Greer, A. Photosensitizer drug delivery via an optical fiber. *J. Am. Chem. Soc.* 2011, 133, 7882–7891. [CrossRef] [PubMed]
63. Gollnick, K. Type II photooxygenation reactions in solution. *Adv. Photochem.* 1968, 6, 1–122. [CrossRef]
64. Murthy, R.S.; Bio, M.; You, Y. Low energy light-triggered oxidative cleavage of olefins. *Tetrahedron Lett.* 2009, 50, 1041–1044. [CrossRef]
65. Nkepang, G.; Pogula, P.K.; Bio, M.; You, Y. Synthesis and singlet oxygen reactivity of 1,2-diaryloxyethenes and selected sulfur and nitrogen analogs. *Photochem. Photobiol.* 2012, 88, 753–759. [CrossRef] [PubMed]

66. Bio, M.; Nkepang, G.; You, Y. Click and photo-unclick chemistry of aminoacrylate for visible light-triggered drug release. *Chem. Commun.* 2012, 48, 6517–6519. [CrossRef] [PubMed]

67. Hossion, A.M.L.; Bio, M.; Nkepang, G.; Awuah, S.G.; You, Y. Visible light controlled release of anticancer drug through double activation of prodrug. *ACS Med. Chem. Lett.* 2013, 4, 124–127. [CrossRef]

68. Bio, M.; Rajaputra, P.; Nkepang, G.; Awuah, S.G.; Hossion, A.M.L.; You, Y. Site-specific and far-red-light-activatable prodrug of combretastatin a-4 using photo-unclick chemistry. *J. Med. Chem.* 2013, 56, 3936–3942. [CrossRef]

69. Bio, M.; Rajaputra, P.; Nkepang, G.; Thapa, P.; Woo, S.; You, Y. Anticancer drug released from near ir-activated prodrug overcomes spatiotemporal limits of singlet oxygen. *Bioorgan. Med. Chem.* 2016, 24, 1540–1549. [CrossRef]

70. Nkepang, G.; Bio, M.; Rajaputra, P.; Awuah, S.G.; You, Y. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor. *Bioconjug. Chem.* 2014, 25, 2175–2188. [CrossRef] [PubMed]

71. Thapa, P.; Li, M.; Bio, M.; Rajaputra, P.; Nkepang, G.; Sun, Y.; Woo, S.; You, Y. Far-red light-activatable prodrug of paclitaxel for the combined effects of photodynamic therapy and site-specific paclitaxel chemotherapy. *J. Med. Chem.* 2016, 59, 3204–3214. [CrossRef] [PubMed]

72. Bio, M.; Rajaputra, P.; Lim, I.; Thapa, P.; Tienabeso, B.; Hurst, R.E.; You, Y. Efficient activation of a visible light-activatable cats prodrug through intramolecular photo-unclick chemistry in mitochondria. *Chem. Commun.* 2017, 53, 1884–1887. [CrossRef] [PubMed]

73. Thapa, P.; Li, M.; Bio, M.; Rajaputra, P.; Nkepang, G.; Woo, S.; You, Y. Folate-peg conjugates of a far-red light-activatable paclitaxel prodrug to improve selectivity toward folate receptor-positive cancer cells. *ACS Omega* 2017, 2, 6349–6360. [CrossRef] [PubMed]

74. Hwang, T.J.; Carpenter, D.; Lauffenburger, J.C.; Wang, B.; Franklin, J.M.; Kesselheim, A.S. Failure of investigational drugs in late-stage clinical development and publication of trial results. *JAMA Intern. Med.* 2016, 176, 1826–1833. [CrossRef] [PubMed]

75. Au, J.L.; Abbiati, R.A.; Wientjes, M.G.; Lu, Z. Target site delivery and residence of nanomedicines: Application of quantitative systems pharmacology. *Pharmacol. Rev.* 2019, 71, 157–169. [CrossRef]

76. Knight-Schrijver, V.R.; Chelliah, V.; Cucurull-Sanchez, L.; Le Novere, N. The promises of quantitative systems pharmacology modelling for drug development. *Comput. Struct. Biotechnol. J.* 2016, 14, 363–370. [CrossRef]

77. Biological and Medical Chemistry model for hypokinetic motor symptoms in parkinson’s disease. *Front. Pharmacol.* 2016, 7, 6. [CrossRef]

78. Nilsson, H.; Polak, S.; Jamei, M.; Rostami-Hodjegan, A. Interaction between domperidone and ketoconazole: Toward prediction of consequent qtc prolongation using purely in vitro information. *CPT Pharmaconet. Syst. Pharmacol.* 2014, 3, 1–11. [CrossRef]

79. Harris, J.M.; Chess, R.B. Effect of pegylation on pharmaceuticals. *Nat. Rev. Drug Discov.* 2003, 2, 214–221. [CrossRef]

80. Chen, B.; Pogue, B.W.; Hoopes, P.J.; Hasan, T. Vascular and cellular targeting for photodynamic therapy. *Crit. Rev. Eukaryot. Gene Expr.* 2006, 16, 279–305. [CrossRef] [PubMed]

81. Li, M.; Thapa, P.; Rajaputra, P.; Bio, M.; Peer, C.J.; Figg, W.D.; You, Y.; Woo, S. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: Implications in stimuli-responsive drug delivery system. *J. Pharmacokinet. Pharmacodyn.* 2017, 44, 521–536. [CrossRef] [PubMed]

82. Delves, P.J.; Roitt, I.M. *Encyclopedia of Immunology*, 2nd ed.; Academic Press: San Diego, CA, USA, 1998.

83. Moretto, J.; Chauffert, B.; Ghiringhelli, F.; Aldrich-Wright, J.R.; Bouyer, F. Discrepancy between in vitro and in vivo antitumor effects of new metal-labeled paclitaxel. *Investig. New Drugs* 2011, 29, 1164–1176. [CrossRef] [PubMed]

84. Henderson, A.S. The ethology of abnormal illness behaviour. *Psychiatr. Med.* 1987, 5, 25–28. [PubMed]

85. Matesanz, R.; Barasoini, I.; Yang, C.G.; Wang, L.; Li, X.; de Ines, C.; Coderch, C.; Gago, F.; Barbero, J.J.; Andreu, J.M.; et al. Optimization of taxane binding to microtubules: Binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. *Chem. Biol.* 2008, 15, 573–585. [CrossRef]
87. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part three-photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. *Photodiagn. Photodyn. Ther.* 2005, 2, 91–106. [CrossRef]

88. Bellnier, D.A.; Dougherty, T.J. A preliminary pharmacokinetic study of intravenous photofrin in patients. *J. Clin. Laser Med. Surg.* 1996, 14, 311–314. [CrossRef]

89. Brun, P.H.; DeGroot, J.L.; Dickson, E.F.; Farahani, M.; Pottier, R.H. Determination of the in vivo pharmacokinetics of palladium-bacteriopheophorbide (WST09) in emt6 tumour-bearing balb/c mice using graphite furnace atomic absorption spectroscopy. *Photochem. Photobiol. Sci.* 2004, 3, 1006–1010. [CrossRef]

90. Ismail, M.S.; Dressler, C.; Koeppe, P.; Senz, R.G.; Roder, B.; Weitzen, H.; Berlien, H.P. Pharmacokinetic analysis of octa-alpha-butyloxy-zinc phthalocyanine in mice bearing lewis lung carcinoma. *J. Clin. Laser Med. Surg.* 1997, 15, 157–161. [CrossRef]

91. Zuk, M.M.; Rihter, B.D.; Kenney, M.E.; Rodgers, M.A.; Kreimer-Birnbaum, M. Pharmacokinetic and tissue distribution studies of the photosensitizer bis(di-isobutyl octadecylsiloxy)silicon 2, 3-naphthalocyanine (isobosinc) in normal and tumor-bearing rats. *Photochem. Photobiol.* 1994, 59, 66–72. [CrossRef]

92. Alvarez, M.G.; Moran, F.; Yslas, E.I.; Vittar, N.B.; Bertuzzi, M.; Durantini, E.N.; Rivarola, V. Pharmacokinetic and tumour-photosensitizing properties of methoxyphenyl porphyrin derivative. *Biomed. Pharmacother.* 2003, 57, 163–168. [CrossRef]

93. Egorin, M.J.; Zuhowski, E.G.; Sentz, D.L.; Dobson, J.M.; Callery, P.S.; Eiseman, J.L. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pe4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent. *Cancer Chemother. Pharmacol.* 1999, 44, 283–294. [CrossRef] [PubMed]

94. Thomas, N.; Tirand, L.; Chatelut, E.; Plenat, F.; Frochot, C.; Dodeller, M.; Guillemin, F.; Barberi-Heyob, M. Tissue distribution and pharmacokinetics of an atwlppr-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice. *Photochem. Photobiol. Sci.* 2008, 7, 433–441. [CrossRef] [PubMed]

95. Castano, A.P.; Demidova, T.N.; Hamblin, M.R. Mechanisms in photodynamic therapy: Part one-photosensitizers, photochemistry and cellular localization. *Photodiagn. Photodyn. Ther.* 2004, 1, 279–293. [CrossRef]

96. Li, M.; Nguyen, L.; Subramaniyan, B.; Bio, M.; Peer, C.J.; Kindrick, J.; Figg, W.D.; Woo, S.; You, Y. Pbpk modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. *J. Control. Release* 2019, 308, 86–97. [CrossRef] [PubMed]

97. Sparreboom, A.; van Tellingen, O.; Nooijen, W.J.; Beijnen, J.H. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle cremophor el. *Cancer Res.* 1996, 56, 2112–2115.

98. Chen, B.; Pogue, B.W.; Hoopes, P.J.; Hasan, T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 2005, 61, 1216–1226. [CrossRef]